Skip to content
sellWeak cluster of 310b5-1 plan

SVF Endurance (Cayman) Ltd sold $1.8M of VIR

owner at Vir Biotechnology, Inc.. 298,649 shares at an average of $6.07, traded Oct 22, 2025, filed Oct 24, 2025.

Warning score
32
Value
$1.8M
298,649 shares
Holdings after
14,711,635
-2% from before
From 52-week low
+43%
low $4.28, close $6.12
From 52-week high
-51%
high $12.48, as of Oct 22, 2025

Score components

  • Role
    10% owner
    +12
  • Trade size
    $1.8M at market
    +25
  • Share of holdings sold
    Sold 2.0% of holdings
    0
  • Cluster
    3 insiders selling within 14 days
    +15
  • 10b5-1 plan
    Pre-scheduled under a 10b5-1 plan
    -20

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

This signal so far: 1m -5.0%, 3m +26.4%, 6m +73.4%.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

VIROct 12, 2026 · close 11.30
Since filing Oct 24, 2025: +89.0%SPY +16.1% · excess +72.8%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001493152-25-019309, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Oct 22, 2025SOpen-market sale
Common Stockindirect: See footnote10b5-1
-144,266$6.15$888k14,866,018Oct 24, 2025
Oct 23, 2025SOpen-market sale
Common Stockindirect: See footnote10b5-1
-154,383$5.99$925k14,711,635Oct 24, 2025

Related signals

Other insiders at Vir Biotechnology, Inc. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
13Weak
VIRsell 210b5-1
Vir Biotechnology, Inc.
Janet Napolitano
director
$30k
3,200 shares
-13%
3Weak
VIRsell 210b5-1
Vir Biotechnology, Inc.
Brent Sabatini
SVP, Chief Accounting Officer
$3,582
379 shares
-1%
7Weak
VIRsell10b5-1
Vir Biotechnology, Inc.
Vicki L Sato
director
$221k
22,000 shares
-2%
40Moderate
VIRsell 310b5-1
Vir Biotechnology, Inc.
Marianne De Backer
President and CEO
$664k
72,559 shares
-7%
22Weak
VIRsell 310b5-1
Vir Biotechnology, Inc.
Vicki L Sato
director
$200k
22,000 shares
-2%
23Weak
VIRsell 310b5-1
Vir Biotechnology, Inc.
Brent Sabatini
SVP, Chief Accounting Officer
$70k
7,711 shares
-11%
22Weak
VIRsell 610b5-1
Vir Biotechnology, Inc.
Vicki L Sato
director
$209k
22,000 shares
-2%
31Weak
VIRsell 610b5-1
Vir Biotechnology, Inc.
Marianne De Backer
Chief Executive Officer
$141k
14,762 shares
-1%
16Weak
VIRsell 610b5-1
Vir Biotechnology, Inc.
Mark Eisner
EVP and Chief Medical Officer
$34k
3,505 shares
-2%
17Weak
VIRsell 610b5-1
Vir Biotechnology, Inc.
Jason O'Byrne
EVP & Chief Financial Officer
$16k
1,634 shares
-1%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

SVF Endurance (Cayman) Ltd sold $1.8M of VIR | InsiderTell